Gansauge S, Gansauge F, Negri G, Galle P, Müller J, Nüssler A K, Poch B, Beger H G
Department of General Surgery, University of Ulm, Germany.
Int J Pancreatol. 1996 Jun;19(3):171-8. doi: 10.1007/BF02787365.
Anti-p53-autoantibodies (a-p53-aabs) may suppress the development of distant metastases, but not lymph node metastases. This could explain the significantly prolonged survival of patients with UICC stage III tumors who have a-p53-aabs compared to those without a-p53-aabs.
Mutation within the tumor suppressor gene p53 leads to increased intracellular p53 protein levels and an increased antibody formation against this molecule. Altered p53 has been proposed to be associated with poor prognosis, and the present study investigated whether the detection of a humoral response to p53 gives evidence for a prognostic or diagnostic parameter in pancreatic disorders.
We screened 145 patients with pancreatic cancer and 95 patients with chronic pancreatitis for the development of a-p53-aab via ELISA and Western-blotting. p53 expression was examined by immunohistochemistry.
We found that 41% of the tissues of patients suffering from pancreatic carcinoma overexpressed p53, and 15.9% of the patients suffering from pancreatic cancer developed a-p53-aab. In pancreatic cancer, we could exhibit a significant correlation between grading, p53-overexpression, survival, and antibody response against p53. A-p53-aabs were significantly more frequent in patients with stage III tumors (tumors with lymph node metastases, but not distant metastases, p < 0.02).
抗p53自身抗体（a-p53-aabs）可能抑制远处转移的发生，但不能抑制淋巴结转移。这可以解释为什么与没有a-p53-aabs的UICC III期肿瘤患者相比，有a-p53-aabs的患者生存期显著延长。
肿瘤抑制基因p53内的突变导致细胞内p53蛋白水平升高以及针对该分子的抗体形成增加。p53改变被认为与预后不良有关，本研究调查了检测对p53的体液反应是否能为胰腺疾病的预后或诊断参数提供依据。
我们通过酶联免疫吸附测定（ELISA）和蛋白质印迹法筛选了145例胰腺癌患者和95例慢性胰腺炎患者是否产生a-p53-aab。通过免疫组织化学检查p53表达。
我们发现41%的胰腺癌患者组织中p53过表达，15.9%的胰腺癌患者产生了a-p53-aab。在胰腺癌中，我们可以发现分级、p53过表达、生存期和针对p53的抗体反应之间存在显著相关性。III期肿瘤患者（有淋巴结转移但无远处转移的肿瘤）中a-p53-aabs的出现频率显著更高（p < 0.02）。
